Saladax Biomedical has signed a diagnostic agreement with Eilaf Pharma for My5-FU diagnostic test in Egypt and throughout the Middle East North African (MENA) region.
The test will measure the levels of an anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients and allows oncologists to determine the optimal dose of 5-FU for each patient.
Saladax chief marketing officer Adrienne Choma said, "We're happy to be working with Eilaf to provide patients with colorectal cancer in the region a new option to help maximize the therapeutic effect of their chemotherapy."
Eilaf is a new joint stock health care company that promotes products to market- leading positions in Egypt and the MENA region.